CrystalGenomics, Inc. - Product Pipeline Review - 2016

  • ID: 3876127
  • Company Profile
  • 37 pages
  • Global Markets Direct
1 of 4
CrystalGenomics, Inc. - Product Pipeline Review - 2016

Summary

‘CrystalGenomics, Inc. - Product Pipeline Review, 2016’, provides an overview of the CrystalGenomics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CrystalGenomics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CrystalGenomics, Inc.
- The report provides overview of CrystalGenomics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CrystalGenomics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CrystalGenomics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate CrystalGenomics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for CrystalGenomics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CrystalGenomics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

CrystalGenomics, Inc. Snapshot

CrystalGenomics, Inc. Overview

Key Information

Key Facts

CrystalGenomics, Inc. - Research and Development Overview

Key Therapeutic Areas

CrystalGenomics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

CrystalGenomics, Inc. - Pipeline Products Glance

CrystalGenomics, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

CrystalGenomics, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

CrystalGenomics, Inc. - Drug Profiles

CG-400549

Product Description

Mechanism of Action

R&D Progress

CG-200745

Product Description

Mechanism of Action

R&D Progress

CG-026806

Product Description

Mechanism of Action

R&D Progress

CG-036806

Product Description

Mechanism of Action

R&D Progress

polmacoxib

Product Description

Mechanism of Action

R&D Progress

CG-0009

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target Metalloproteinases for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target Nuclear Hormone Receptors for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target Phosphodiesterases for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

CrystalGenomics, Inc. - Pipeline Analysis

CrystalGenomics, Inc. - Pipeline Products by Target

CrystalGenomics, Inc. - Pipeline Products by Route of Administration

CrystalGenomics, Inc. - Pipeline Products by Molecule Type

CrystalGenomics, Inc. - Pipeline Products by Mechanism of Action

CrystalGenomics, Inc. - Recent Pipeline Updates

CrystalGenomics, Inc. - Dormant Projects

CrystalGenomics, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

CrystalGenomics, Inc., Key Information

CrystalGenomics, Inc., Key Facts

CrystalGenomics, Inc. - Pipeline by Indication, 2016

CrystalGenomics, Inc. - Pipeline by Stage of Development, 2016

CrystalGenomics, Inc. - Monotherapy Products in Pipeline, 2016

CrystalGenomics, Inc. - Partnered Products in Pipeline, 2016

CrystalGenomics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

CrystalGenomics, Inc. - Phase II, 2016

CrystalGenomics, Inc. - Phase I, 2016

CrystalGenomics, Inc. - Preclinical, 2016

CrystalGenomics, Inc. - Discovery, 2016

CrystalGenomics, Inc. - Pipeline by Target, 2016

CrystalGenomics, Inc. - Pipeline by Route of Administration, 2016

CrystalGenomics, Inc. - Pipeline by Molecule Type, 2016

CrystalGenomics, Inc. - Pipeline Products by Mechanism of Action, 2016

CrystalGenomics, Inc. - Recent Pipeline Updates, 2016

CrystalGenomics, Inc. - Dormant Developmental Projects,2016

CrystalGenomics, Inc., Subsidiaries 35List of Figures

CrystalGenomics, Inc. - Pipeline by Top 10 Indication, 2016

CrystalGenomics, Inc. - Pipeline by Stage of Development, 2016

CrystalGenomics, Inc. - Monotherapy Products in Pipeline, 2016

CrystalGenomics, Inc. - Pipeline by Target, 2016

CrystalGenomics, Inc. - Pipeline by Route of Administration, 2016

CrystalGenomics, Inc. - Pipeline by Molecule Type, 2016

CrystalGenomics, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll